Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07567326 | Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC | not yet recruiting | Phase 2 | 78 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2026 |
| NCT07568236 | A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) | not yet recruiting | Phase 2 | 54 | Chinese University of Hong KongOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07565389 | Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma(AK112) | not yet recruiting | Phase 2 | 42 | National University Hospital, SingaporeOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07565415 | Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | not yet recruiting | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07285993 | Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET | not yet recruiting | Phase 2 | 15 | Randy YehOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07524894 | Staph Nasal Decolonization to Improve Function and Feeding(SNIFF) | not yet recruiting | Phase 2 | 126 | David PalmaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07561463 | Sacituzumab Tirumotecan for Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07561775 | Adebrelimab Plus S-1 for Resected Cholangiocarcinoma | not yet recruiting | Phase 2 | 40 | Xingjun GuoOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07561983 | Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC(BEACON-Lung) | not yet recruiting | Phase 2 | 39 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562971 | Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)(FIDES) | not yet recruiting | Phase 1 / Phase 2 | 20 | UMC UtrechtOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05776381 | The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp | not yet recruiting | Phase 2 | 110 | Vejle HospitalOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07041788 | Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC | not yet recruiting | Phase 2 | 25 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07535567 | Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma(NimoBenSeq) | not yet recruiting | Phase 2 / Phase 3 | 386 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07539753 | Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases | not yet recruiting | Phase 2 | 46 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07560124 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 286 | AkesoINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07379398 | Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07346677 | Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel | not yet recruiting | Phase 2 | 190 | University of BasrahOTHER | 0 | Apr 28, 2026 | clinicaltrials |
| NCT07381309 | Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM(VVSHIP) | not yet recruiting | Phase 2 | 114 | Jun HuangOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07543783 | Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial | not yet recruiting | Phase 2 | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 28, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07554768 | Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC(RAIN-HNSCC) | not yet recruiting | Phase 2 | 36 | Chen ChunyanOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07554859 | GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 90 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | not yet recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552324 | Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP | not yet recruiting | Phase 2 | 28 | Ruijin HospitalOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT07552649 | Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia(MATCH-Treg) | not yet recruiting | Phase 2 | 28 | Antonio PieriniOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07244978 | Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 49 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07549906 | Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study | not yet recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma(FLOURISH) | not yet recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550920 | Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) | not yet recruiting | Phase 2 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07551414 | Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI | not yet recruiting | Phase 2 | 38 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer(JAZMINE) | not yet recruiting | Phase 1 / Phase 2 | 24 | MedSIROTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07547332 | Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC | not yet recruiting | Phase 2 | 84 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | not yet recruiting | Phase 2 | 20 | Chongqing University Cancer HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07545083 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) | not yet recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT07545213 | Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis | not yet recruiting | Phase 2 | 27 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03301805 | A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer | not yet recruiting | Phase 2 | 40 | Rgene CorporationINDUSTRY | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07015853 | ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | not yet recruiting | Phase 2 | 34 | Stephen ShiaoOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538258 | Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer(Aurora004) | not yet recruiting | Phase 2 | 27 | Yayi HeOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07538271 | A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer(Aurora 005) | not yet recruiting | Phase 2 | 33 | Yayi HeOTHER | 0 | Apr 20, 2026 | clinicaltrials |
| NCT07539779 | Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis | not yet recruiting | Phase 2 / Phase 3 | 196 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07527806 | Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging | not yet recruiting | Phase 2 | 156 | Peking University Cancer Hospital & InstituteOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535762 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | not yet recruiting | Phase 2 | 36 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537777 | Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy | not yet recruiting | Phase 2 | 29 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537972 | Denosumab Strategy for Liver Cancer With Bone Metastases | not yet recruiting | Phase 2 | 50 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07361133 | Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer | not yet recruiting | Phase 2 | 120 | National Cancer Institute, EgyptOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06617286 | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 21 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 5, 2026source: clinicaltrials